skip to Main Content
placeholder

Farough Highlights Features of Core Imaging Criteria

September 10, 2021 – RECIST 1.1 and iRECIST are core criteria for advanced clinical trials and their use are extremely important in terms of FDA approval.

Samira Farough, MD, our Director of Reader Operations, recently discussed the value of RECIST 1.1 and iRECIST and their use in oncology clinical trials in a video with Dr. Elliot K. Fishman, Professor of Radiology, Surgery, Oncology and Urology at Johns Hopkins Hospital.

Watch the session at YouTube.com.

Back To Top